NY-BREGAL-SAGEMOUNT
10.1.2023 09:01:39 CET | Business Wire | Press release
Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, today announced a strategic growth investment in Enhesa (the “Company”), a leading provider of regulatory and sustainability intelligence worldwide. As part of the transaction, Sagemount will acquire ICG’s minority stake in Enhesa, with existing investor CGE Partners (“CGE”) retaining its majority stake in the Company. Financial terms of the transaction were not disclosed.
With its global headquarters in Brussels, Belgium and U.S. headquarters in Arlington, VA, Enhesa empowers multinational corporations worldwide to help create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions, supported by a team of over 100 in-house legal experts. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future.
“We are thrilled to be partnering with Sagemount as we enter our next stage of growth,” said Peter Schramme, CEO of Enhesa. “With their and CGE’s support and deep industry expertise, we believe we are well-positioned to further invest in our current offerings as well as accelerate new content coverage, use cases, and customer verticals.”
“We see tremendous growth ahead for Enhesa as a result of the Company’s strong product-market fit and tangible customer ROI,” said Pavan Tripathi, Partner at Sagemount. “Enhesa has an impressive track record of consistently retaining and growing its customer relationships as well as expanding new content offerings and jurisdictional coverage through both organic and inorganic growth initiatives. We are excited to be working with Peter, the Enhesa team, and CGE.”
David Greenbaum, Vice President at Sagemount, added, “For enterprises that operate, manufacture, and sell globally, Enhesa is by far the leading third-party content provider, allowing companies to monitor relevant Environmental, Health, & Safety (“EHS”) and other regulations across the enterprise significantly faster and more accurately than internal teams or disparate, regional third-party content providers.”
"We have enjoyed a highly successful partnership with Enhesa since acquiring the Company in 2020. Under CGE’s ownership to date, Enhesa has meaningfully scaled its business, expanded its industry-leading regulatory compliance content set from EHS to also include Product Compliance and Sustainability Intelligence, and completed five strategic add-on acquisitions," CGE commented. "We look forward to continuing to support Enhesa in its next chapter of growth alongside Sagemount."
Sagemount’s investment was led by Pavan Tripathi, Sandeep Swaminathan, David Greenbaum, Harrison Boyajian, and Stephanie Li. Sagemount was advised by Raymond James and Goodwin Procter. Enhesa and CGE were advised by Houlihan Lokey and Travers Smith.
About Enhesa
Enhesa is the leading provider of regulatory and sustainability intelligence worldwide. Headquartered in Brussels, with offices in Washington, DC, Williamsport, PA, Toronto, the United Kingdom, Tokyo, Shanghai, and Portugal, Enhesa empowers multinational corporations worldwide to create a more sustainable future by positively impacting the environment and ensuring the health and safety of their employees and customers. Bringing together some of the world’s most comprehensive data sets, AI-powered analytics, and renowned subject matter experts in the areas of global operations, product, and chemicals management compliance and sustainability, Enhesa provides actionable compliance intelligence in over 40 languages across more than 300 jurisdictions. Navigating the fast-changing regulatory landscape, Enhesa helps corporations meet their compliance and sustainability needs with confidence, now and in the future. For more information on Enhesa, go to the firm's website at www.enhesa.com.
About Sagemount
Bregal Sagemount is a leading growth-focused private capital firm with more than $6.0 billion of capital raised. The firm provides flexible capital and strategic assistance to market-leading companies in high-growth sectors across a wide variety of transaction situations. Bregal Sagemount has invested in over 70 companies in a variety of sectors, including software, information / data services, financial technology & specialty finance, digital infrastructure, healthcare IT, and business & consumer services. The firm has offices in New York, Palo Alto, and Dallas. For more information, visit the Sagemount website: www.sagemount.com or follow us on LinkedIn.
About CGE
CGE Partners is a European mid-market investment fund. CGE invests in tech-enabled businesses facilitating the transition to a more digital, renewable, secure, and compliant future, providing capital and expertise to accelerate expansion in global markets. For more information, visit the CGE website: https://cge-partners.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005348/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom